Deutsche Bank Cuts Novartis to Hold After Second Clinical Setback
Deutsche Bank lowered its recommendation on Novartis from Buy to Hold and trimmed the price target to 120 Swiss francs from 140 francs following a second successive clinical trial disappointment. Analyst Emmanuel Papadakis pointed to a del-desiran miss in DM1 and the earlier pelacarsen failure as evidence that recent acquisitions and deal returns h…